Cefuroxime axetil: Difference between revisions
Appearance
Content deleted Content added
No edit summary Tags: Mobile edit Mobile web edit |
Rescuing 1 sources and tagging 0 as dead. #IABot (v1.5beta) |
||
Line 46: | Line 46: | ||
}} |
}} |
||
'''Cefuroxime axetil''' is a second generation oral [[cephalosporin]] [[antibiotic]]. It was discovered by Glaxo now [[GlaxoSmithKline]] and introduced in 1987 as '''Zinnat'''.<ref>{{cite web | url = http://www.gsk.com/about/history.htm | title = Our history - About GSK | publisher = GlaxoSmithKline}}</ref> It was approved by FDA on Dec 28, 1987.<ref>http://www.drugs.com/monograph/cefuroxime-axetil.html</ref> It is available by [[GlaxoSmithKline|GSK]] as Ceftin in US<ref>https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductsByName#C</ref> and Ceftum in India.<ref>{{Cite web | url = http://www.gsk-india.com/product-antiinfective.html | title = Our products | publisher = GlaxoSmithKline}}</ref> |
'''Cefuroxime axetil''' is a second generation oral [[cephalosporin]] [[antibiotic]]. It was discovered by Glaxo now [[GlaxoSmithKline]] and introduced in 1987 as '''Zinnat'''.<ref>{{cite web | url = http://www.gsk.com/about/history.htm | title = Our history - About GSK | publisher = GlaxoSmithKline | deadurl = yes | archiveurl = https://web.archive.org/web/20110514143603/http://www.gsk.com/about/history.htm | archivedate = 2011-05-14 | df = }}</ref> It was approved by FDA on Dec 28, 1987.<ref>http://www.drugs.com/monograph/cefuroxime-axetil.html</ref> It is available by [[GlaxoSmithKline|GSK]] as Ceftin in US<ref>https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductsByName#C</ref> and Ceftum in India.<ref>{{Cite web | url = http://www.gsk-india.com/product-antiinfective.html | title = Our products | publisher = GlaxoSmithKline}}</ref> |
||
It is an acetoxyethyl ester [[prodrug]] of [[cefuroxime]] which is effective orally.<ref>{{cite book | title = Drug Discovery: A History | author = Walter Sneader | publisher = John Wiley, Chichester, UK | isbn = 0-471-89979-8 | page = | url = https://books.google.com/books?id=Cb6BOkj9fK4C&pg=PA326 }}</ref> The activity depends on ''[[in vivo]]'' [[hydrolysis]] and release of cefuroxime tablets. |
It is an acetoxyethyl ester [[prodrug]] of [[cefuroxime]] which is effective orally.<ref>{{cite book | title = Drug Discovery: A History | author = Walter Sneader | publisher = John Wiley, Chichester, UK | isbn = 0-471-89979-8 | page = | url = https://books.google.com/books?id=Cb6BOkj9fK4C&pg=PA326 }}</ref> The activity depends on ''[[in vivo]]'' [[hydrolysis]] and release of cefuroxime tablets. |
Revision as of 17:11, 1 August 2017
Clinical data | |
---|---|
Trade names | Zinnat, Ceftin, Ceftum |
Other names | Cefuroxime 1-acetoxyethyl ester |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | well absorbed |
Metabolism | Cefuroxime is not metabolized, Axetil is metabolized to acetaldehyde and acetic acid. |
Excretion | Urine |
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.166.374 |
Chemical and physical data | |
Formula | C20H22N4O10S |
Molar mass | 510.475 g/mol g·mol−1 |
3D model (JSmol) | |
| |
|
Cefuroxime axetil is a second generation oral cephalosporin antibiotic. It was discovered by Glaxo now GlaxoSmithKline and introduced in 1987 as Zinnat.[1] It was approved by FDA on Dec 28, 1987.[2] It is available by GSK as Ceftin in US[3] and Ceftum in India.[4]
It is an acetoxyethyl ester prodrug of cefuroxime which is effective orally.[5] The activity depends on in vivo hydrolysis and release of cefuroxime tablets.
See also
References
- ^ "Our history - About GSK". GlaxoSmithKline. Archived from the original on 2011-05-14.
{{cite web}}
: Unknown parameter|deadurl=
ignored (|url-status=
suggested) (help) - ^ http://www.drugs.com/monograph/cefuroxime-axetil.html
- ^ https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductsByName#C
- ^ "Our products". GlaxoSmithKline.
- ^ Walter Sneader. Drug Discovery: A History. John Wiley, Chichester, UK. ISBN 0-471-89979-8.